Literature DB >> 10643081

Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: application to emergence of lamivudine-resistant hepatitis B virus.

N J Burroughs1, D Pillay, D Mutimer.   

Abstract

Bayesian analysis using a virus dynamics model is demonstrated to facilitate hypothesis testing of patterns in clinical time-series. Our Markov chain Monte Carlo implementation demonstrates that the viraemia time-series observed in two sets of hepatitis B patients on antiviral (lamivudine) therapy, chronic carriers and liver transplant patients, are significantly different, overcoming clinical trial design differences that question the validity of non-parametric tests. We show that lamivudine-resistant mutants grow faster in transplant patients than in chronic carriers, which probably explains the differences in emergence times and failure rates between these two sets of patients. Incorporation of dynamic models into Bayesian parameter analysis is of general applicability in medical statistics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10643081      PMCID: PMC1690468          DOI: 10.1098/rspb.1999.0932

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  7 in total

1.  Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation.

Authors:  P A Cane; D Mutimer; D Ratcliffe; P Cook; G Beards; E Elias; D Pillay
Journal:  Antivir Ther       Date:  1999

2.  High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation.

Authors:  D Mutimer; D Pillay; E Dragon; H Tang; M Ahmed; K O'Donnell; J Shaw; N Burroughs; D Rand; P Cane; B Martin; S Buchan; E Boxall; S Barmat; K Gutekunst; P McMaster; E Elias
Journal:  J Hepatol       Date:  1999-04       Impact factor: 25.083

3.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.

Authors:  K Chayama; Y Suzuki; M Kobayashi; M Kobayashi; A Tsubota; M Hashimoto; Y Miyano; H Koike; M Kobayashi; I Koida; Y Arase; S Saitoh; N Murashima; K Ikeda; H Kumada
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

4.  Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.

Authors:  S E Davies; B C Portmann; J G O'Grady; P M Aldis; K Chaggar; G J Alexander; R Williams
Journal:  Hepatology       Date:  1991-01       Impact factor: 17.425

5.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

6.  Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro.

Authors:  J S McMillan; T Shaw; P W Angus; S A Locarnini
Journal:  Hepatology       Date:  1995-07       Impact factor: 17.425

7.  Viral dynamics in hepatitis B virus infection.

Authors:  M A Nowak; S Bonhoeffer; A M Hill; R Boehme; H C Thomas; H McDade
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

  7 in total
  2 in total

1.  Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.

Authors:  Simon D W Frost; Javier Martinez-Picado; Lidia Ruiz; Bonaventura Clotet; Andrew J Leigh Brown
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 2.  Combination chemotherapy for hepatitis B virus: the path forward?

Authors:  T Shaw; S Locarnini
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.